6/14
08:55 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
6/7
09:04 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
High
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
5/31
08:40 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Medium
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
5/28
08:24 am
phat
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
5/28
08:00 am
phat
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
5/24
01:04 pm
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
5/17
10:03 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
5/15
08:20 am
phat
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting [Yahoo! Finance]
Low
Report
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting [Yahoo! Finance]
5/15
08:00 am
phat
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
Low
Report
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
5/13
11:16 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/10
09:33 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
Medium
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
5/9
02:05 pm
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Medium
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
5/9
08:12 am
phat
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Neutral
Report
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/9
08:00 am
phat
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Low
Report
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
5/3
05:06 pm
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Medium
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
5/3
07:43 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $24.00 price target on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $24.00 price target on the stock.
4/29
08:00 am
phat
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
Medium
Report
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
4/26
12:00 pm
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
4/22
03:30 am
phat
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Low
Report
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
4/22
03:30 am
phat
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Low
Report
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
4/19
03:09 pm
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
4/11
08:06 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
High
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
4/3
08:00 am
phat
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Medium
Report
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/1
08:08 am
phat
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
Low
Report
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $26.00 price target on the stock.
3/26
08:12 am
phat
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid” [Yahoo! Finance]
Low
Report
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid” [Yahoo! Finance]